We would like to express our opinion regarding a Parise and Caggiano paper recently published in your journal. We certainly believe this is a great contribution, since it found that node-negative HER2 (+) breast cancer patients have better survival contrary to the common knowledge. This finding could reflect the consequences of targeted therapies that are changing the natural history of the disease. However, we think that such an interesting analysis could also have been done with stage III and IV patients, since this group of people could benefit greatly from these findings. In fact, new guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even for life if they do not show signs of progression. Additionally, we would like to discuss the value of adding the Ki-67 marker to the classification proposed by the authors, because several papers consider it an important prognostic factor.
I wish to congratulate Parise and Caggiano for their article in which they retrospectively evaluated data from female patients with node-negative primary invasive breast cancer from the California Cancer Registry [1] . This is a great contribution to the understanding on how these histopathological factors affect the natural history of this disease, as well as its response to treatment. Several studies have shown association between these factors before [2] , but this research is explicit in mentioning that HER2 (+) patients have better survival contrary to the common knowledge [2] . This finding could be explained by the use of new drugs that target specifically the HER receptor, transforming its presence from hazardous to protective as long as the specific therapy is provided.
One group who could benefit greatly from this change in risk directionality are the stage III and IV breast cancer patients; however, they were not included in this study.
Having access to the California Cancer registry, we did not find a clear reason why the authors did not include these patients as they did in their 2009 paper [3] when they evaluated an early immunohistological classification. The authors did analyze survival with the classification currently proposed in their 2014 research [4] ; however, as in the current study, they excluded stage IV patients. New guidelines now recommend the use of HER2-specific therapy for stage IV patients with positive markers, even lifelong if they do not show signs of progression [5] . In these cases, it will be very useful to know, if, in fact, the patients with positive HER2 markers have better outcomes than cases with other combination of markers. We acknowledge that a full analysis would have required adjustments by treatment and other information that might not be available in the Registry, but we believe efforts should be done to analyze big datasets not only in patients with operable stages but in all of them.
Another evaluation we considered worthwhile of performing is to analyze the effect of the Ki-67 marker, since several studies have shown it as an important prognostic factor, closely related to molecular classification [6] . The authors did discuss the value of using the Ki-67 in a previous paper [4] , and concluded that the genomic grade index may be a more valuable alternative instead of the Ki-67. Even if not available in all cases, we believe that survival * Alejandra F. Pichilingue-Febres alejandrapf29@gmail.com analysis categorized by Ki67 in conjunction with the molecular matrix of eight possibilities proposed by the authors could be very useful to clarify which specific combination provides a better survival.
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